

References

I-169

1. Hensley ML, Patel SR, von Mehren M, et al. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. *Gynecologic Oncology*. 2017;531–537.
2. Morioka H, Takahashi S, Araki N, et al. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. *BMC Cancer*. 2016;1-8.
3. Rafia R, Simpson E, Stevenson M, Papaioannou D. Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal. *PharmacoEconomics*. 2013;471–478.
4. MICROMEDEX®SOLUTIONS Compendia. 2019. Trabectedin.
5. Clinical Pharmacology Compendia. [database online]. 2019. Tampa FL: Gold Standard, Inc. Trabectedin.
6. NCCN Drugs & Biologics Compendium™. Trabectedin. 2019. National Comprehensive Cancer Network (NCCN).
7. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.
8. Patel S, von Mehren M, Reed D, et al. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. *Cancer*. 2019;125(15):2610-2620.